BioPharma Dive April 24, 2024
While the company is eager to diversify beyond neuroscience, CEO Chris Viehbacher said that in the near-term any dealmaking would likely focus on collaborations and early-stage assets.
Investors who had hoped Biogen would do another flashy deal this year may not want to hold their breath, as the biotechnology company signaled that, at least for the time being, it isn’t looking to make any large purchases.
“If something really extraordinary came along, I suppose we’d look at it,” Biogen CEO Chris Viehbacher said during an earnings call Wednesday. “But I don’t think where we sit right now we’d be thinking about doing anything this year on an acquisition front, not certainly of any size.”
That’s not to say the company...
Today's Sponsors
Today's Sponsor